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Metastatic progression of cancer is associated with
poor outcome, and here we examine metabolic
changes underlying this process. Although aerobic
glycolysis is known to promote metastasis, we have
now identified a different switch primarily affecting
mitochondria. The switch involves overload of the
electron transport chain (ETC) with preserved mito-
chondrial functions but increased mitochondrial
superoxide production. It provides a metastatic
advantage phenocopied by partial ETC inhibition,
another situation associatedwith enhanced superox-
ide production. Both cases involved protein tyrosine
kinases Src and Pyk2 as downstream effectors.
Thus, two different events, ETC overload and partial
ETC inhibition, promote superoxide-dependent
tumor cell migration, invasion, clonogenicity, and
metastasis. Consequently, specific scavenging of
mitochondrial superoxide with mitoTEMPO blocked
tumor cell migration and prevented spontaneous tu-
mor metastasis in murine and human tumor models.
INTRODUCTION
Tumors are highly heterogeneous in all phenotypic features
including glucose metabolism. Although glycolysis is coupled
to oxidative phosphorylation (OXPHOS) in oxygenated tumor
cells, some malignant cells are subject to fluctuations in oxygen
availability and, therefore, rely on glycolysis uncoupled from
OXPHOS for energy production (Dewhirst, 2009). From an ener-
getic standpoint, it is surprising that some cancer cells also
performaerobic glycolysis (known as theWarburg effect), charac-
terized by an increased normoxic flux of glucose to lactate (War-
burg, 1956). However, this particular metabolic phenotype is
shared with nonmalignant proliferating cells and is therefore
thought to reflect increased biosynthetic plasticity (VanderHeiden
et al., 2009; Ward and Thompson, 2012). Although it sometimes
results from mutations (Frezza et al., 2011), there is evidence
that mitochondria generally retain full oxidative capacities in solid754 Cell Reports 8, 754–766, August 7, 2014 ª2014 The Authorstumors and that aerobic glycolysis can often be reverted (Faubert
et al., 2013; Vaupel and Mayer, 2012), suggesting that this meta-
bolic activity generally results from reversible changes that could
be targeted pharmacologically. Thus, mitochondria actively
contribute to aerobic glycolysis by producing cataplerotic inter-
mediates and reducing equivalents to sustain cell growth and
cell cycling (Anastasiou et al., 2011; Vander Heiden et al., 2009).
Tumormetastasis is a leading cause of cancer death. Themet-
astatic switch marking the onset of metastatic dissemination
corresponds to the acquisition of specific traits by tumor cells,
including migration, invasion, and survival in the blood stream
(Gupta and Massague´, 2006; Roussos et al., 2011). Three main
lines of evidence led us to hypothesize that metastasis is under
metabolic control. First, PET with the glucose analog tracer
[18]-F-fluorodeoxyglucose (FDG) is routinely used for the clinical
detection and imaging of tumormetastasis (Gambhir et al., 2001).
This application is based on the observation that the vastmajority
ofmetastases trap farmore glucose than normal tissues (with the
exception of the brain), which has often been related tometabolic
characteristics already acquired at the primary tumor site (Van-
der Heiden et al., 2009). Second, aerobic glycolysis could offer
protection against oxidative damage and cell death when tumor
cells transit in oxygenated blood (Porporato et al., 2011). Third, a
mitochondrial defect corresponding to an inactivating mutation
of respiratory chain complex I has been found in a metastatic
mouse Lewis lung carcinoma cell line and was absent in weakly
metastatic parental cells (Ishikawa et al., 2008a). Experimentally,
the transfer of mtDNA from highly to weakly metastatic cells
increased their metastatic potential in mice.
It is estimated that on average 106 tumor cells per gram of
tumor are shed in the circulation daily (Chang et al., 2000). Of
these cells, only a few, termed metastatic progenitors, are able
to generatemetastases in distant organs. In this study, we tested
whether Warburg-phenotype tumor cells constitute a population
of metastatic progenitors. We observed that tumor cell migra-
tion, invasion, clonogenicity, metastatic take, and spontaneous
metastasis in mice are promoted by the natural selection of a
mitochondrial phenotype associated with superoxide produc-
tion, which was phenocopied by experimentally targeting the
electron transport chain (ETC).We also report that pharmacolog-
ical scavenging of mitochondrial superoxide prevents metastatic
dissemination from primary orthotopic tumors in mice.
Figure 1. The Experimental Selection of
Superinvasive Tumor Cells Correlates with
Increased Mitochondrial Activity
(A–C) SiHa-F3 cells were isolated from a total
population of WT SiHa tumor cells following three
consecutive rounds of in vitro invasion in Matrigel-
coated transwells (model shown in A). Compara-
tive (B) invasion and (C) migration assays (n = 3).
(D and E) Glucose consumption (D) and lactate
production (E) over 24 hr (n = 3).
(F) Mitochondrial oxygen consumption of adherent
cells (n = 8).
(G) Intracellular succinate levels (n = 5).
All data represent means ± SEM. *p < 0.05, **p <
0.01, ***p < 0.005, ns, not significant compared to
SiHa-WT by Student’s t test.RESULTS
In Vitro Selection of Superinvasive Tumor Cells
Coselects Increased Mitochondrial Activity
To test the contribution of glycolysis to tumor metastasis, we
first used a correlative approach in vitro. Invasion is a funda-
mental characteristic of metastatic tumor cells (Nguyen et al.,
2009). A wild-type (WT) population of oxidative SiHa human
cervix squamous cell carcinoma cells (Sonveaux et al., 2008)
was subjected to three rounds of in vitro selection (Figure 1A)
resulting in the isolation of SiHa-F3 cells with enhanced inva-
sive activity (Figure 1B). The cells, which had also gained an
increased migratory phenotype (Figure 1C), were analyzed for
glucose metabolism. They were characterized by an enhance-
ment of glucose uptake that was surprisingly not associated
with higher lactate production (Figures 1D and 1E). Adherent
SiHa-F3 cells showed increased mitochondrial O2 consumption
(Figure 1F) and succinate accumulation (Figure 1G) compared
to WT cells.
In Vivo Selection of Supermetastatic Tumor Cells
Coselects for Increased Levels of TCA Intermediates
The above model was instrumental in postulating the existence
of a metabolic phenotype associated with tumor metastasis,
which was confirmed in vivo with mouse melanoma tumor cells.
B16F10 cells, which are only moderately metastatic in sponta-
neous assays (Brown et al., 2002), were subjected to rounds ofCell Reports 8, 754–76in vivo selection for increased metastatic
activity (Figure 2A). B16-M1 to M5 tumor
cells were expanded after one to five
rounds of selection, with two parallel
selections producing two distinct popula-
tions of metastatic cells, M2/3a and M4/
5b. As shown for B16-M4b in Figure 2B,
in vivo selection significantly enhanced
spontaneous metastatic activities to the
lungs. Selected cells had also gained
improved invasiveness (Figure 2C) and
clonogenicity (Figure 2D). Clonogenicity,
in particular, was increased upon selec-
tion compared to the weakly metastaticB16F10 and the nonmetastatic B16F1 variants (Fidler, 1975).
From a metabolic standpoint, we found no difference in the
rate of glucose uptake and lactate release (Figure 2E) and mito-
chondrial oxygen consumption (Figure 2F) when comparing
adherent B16F10 to B16-M2a and B16-M4b. Cells freshly iso-
lated from primary tumors generated with B16F10 served to
verify that in vivo implantation did not account for changes (Fig-
ure 2E). Although the glycolytic flux and oxygen consumption
were unchanged, we detected increased succinate (Figure 2G)
and 2-oxoglutarate (Figure S1A) production in supermetastatic
cells, suggesting a TCA dysfunction. Compared to B16F10,
B16-M4b possessed larger mitochondria with numerous cristae
(Figure 2H). This mitochondrial phenotype did not influence ATP
levels (Figure 2I) and tumor cell proliferation (Figure S1B). The
relative contribution of OXPHOS to ATP synthesis was tested
by adding rotenone, and the contribution of glycolysis under
hypoxic conditions; no difference was found between B16F10
and B16-M4b cells (Figure 2I). Collectively, these data provide
a positive correlation between the metastatic activities of cancer
cells and a mitochondrial switch corresponding to aberrant TCA
cycle activity, similar to what we found in superinvasive SiHa
cells (Figure 1).
Partial Electron Transport Chain Inhibition Promotes
Tumor Cell Migration
To provide direct evidence of a mitochondrial contribution to tu-
mor metastasis in our models, we first generated r0 cells with6, August 7, 2014 ª2014 The Authors 755
Figure 2. The Experimental In Vivo Selection of Supermetastatic Tumor Cells Is Associated with a TCA Cycle Overload
(A) B16-M1 to B16-M5 cells were, respectively, retrieved after one to five rounds of in vivo selection for lung metastasis from a primary subcutaneous tumor
initially generated with B16F10 tumor cells (model shown in A, where expected lung metastasis density is represented by asterisks).
(B) Spontaneous lung metastasis detected 30 days after the subcutaneous implantation of a primary tumor (nR 5).
(C) Overnight in vitro invasion assay (n = 6).
(D) Colony formation assay (n = 3).
(E) Glucose consumption and lactate production over 24 hr (n = 4).
(F) Mitochondrial oxygen consumption of adherent cells (n = 8).
(G) Intracellular succinate levels (n = 4).
(H) Representative electron microscopy pictures. Arrows indicate giant mitochondria. Bar, 1 mm.
(I) Intracellular ATP levels after 8 hr of culture with the indicated treatments.
All data represent means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005, ns, not significant compared to B16F10; ##p < 0.01 compared to B16F1, by Student’s t test
(B and C) or one-way ANOVA (D–G and I). See also Figure S1.
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dysfunctional mitochondria (Sonveaux et al., 2008). SiHa-r0-D2
cells, further subcloned from the total SiHa-r0 population, were
devoid of intact mitochondria (Figure S2A). Compared to WT,
SiHa-r0 and SiHa-r0-D2 showed partial and total impairment
of mitochondrial respiration, respectively (Figure 3A). It was
coherent with a progressive decline in mitochondria-encoded
cytochrome coxidase I (mt-CO1protein expression, FigureS2B),
and glycolytic compensation (Figure 3B). In vitro assays revealed
increased migratory (Figure 3C) and invasive (Figure 3D) activ-
ities of SiHa-r0 compared to WT. Strikingly, in the same exper-
imental conditions, SiHa-r0-D2 showed a close to complete
impairment of migration and invasion compared to SiHa-r0
and WT cells (Figures 3C and 3D). These experiments were
key in showing that mitochondria must be present, active but
dysfunctional, to promote the migratory phenotype. We there-
fore aimed to identify the nature of possible dysfunctions with
more accurate approaches.
Others previously reported that mutations partially inactivat-
ing ETC complex I and associated with increased mitochondrial
reactive oxygen species (mtROS) production can promote tu-
mor metastasis (Ishikawa et al., 2008a). To go beyond these
findings, we reasoned that any intervention bottlenecking the
ETC could promote tumor cell migration, which was tested
with WT SiHa cells in transwells. Accordingly, low-dose rote-
none (targeting respiration complex I; Sherer et al., 2003), 3-
nitropropionate (3-NP, inhibiting respiratory complex II; Maciel
et al., 2004), and a partial knockdown of mt-CO1 (complex IV;
Tsukihara et al., 1996; Figure S2C) all highly significantly pro-
moted SiHa cell migration (Figure 3E). Moderate complex III in-
hibition also enhanced tumor cell migration (tested in the B16
model, detailed after). That partial ETC inhibition promotes tu-
mor cell migration was confirmed using 4T1 mouse mammary
carcinoma cells treated with rotenone (Figure S2D). Rotenone
also allowed us to identify the existence of a phenotypic win-
dow, with doses ranging from 1 to 100 nM promoting SiHa tumor
cell migration, whereas doses lower than 1 nM or higher than
100 nM did not (Figure 3F). It is of note that rotenone below
1 nM would have little or no pharmacological effect and at
1 mM would typically cause full respiration blockade (Brown
and Nurse, 2008).
Mitochondrial ROS Promote and mitoTEMPO Inhibits
Tumor Cell Migration
Partial ETC inhibition may result in incomplete oxygen reduction
to yield superoxide (Brandon et al., 2006), a precursor of other
promigratory ROS (Cannito et al., 2010). Accordingly, rotenone
at a dose of 10 nM optimally promoting migration (Figure 3F)
also enhanced mitochondrial superoxide production in WT
SiHa cells, as detected with mitoSOX (Zhou et al., 2011; Fig-
ure 3G). MitoSOX was not sensitive enough to show increased
superoxide production by other ETC inhibitors; we therefore
tested mtROS contribution with specific antioxidants in migra-
tion assays (Tsukihara et al., 1996). We first found that N-
acetyl-L-cysteine (NAC) totally inhibited the promigratory effects
of ETC bottlenecking (Figure 3E). It did not impact basal cell
migration. Similar to NAC, theH2O2 scavenger Ebselen (Schewe,
1995) had no basal effect but countered the induction of SiHa cell
migration by rotenone and mt-CO1 inhibition (Figure 3H).Involvement of upstream mitochondrial superoxide was probed
with mitoTEMPO, a specific scavenger of mitochondrial super-
oxide (Dikalova et al., 2010; Nazarewicz et al., 2013a). Mito-
TEMPO recapitulated the effects of Ebselen in the same assays
(Figure 3I), whereas methyltriphenylphosphonium (mTPP), used
as a control, did not prevent rotenone-induced SiHa cell migra-
tion (Figure S2E). Together, our data pointed toward mtROS as
key molecular intermediates enhancing tumor cell migration
upon partial ETC inhibition.
If mtROS promoted the migration of cells with dysfunctional
mitochondria, it would also confer a migratory phenotype to
naturally selected tumor cells with dysfunctional TCA cycle
activity. To test this hypothesis, we used SiHa-F3 and B16-
M4b cells. We first found that, compared to their WT counter-
parts, both SiHa-F3 (Figure 3J, left panel) and B16-M4b
(Figure 3K, left panel) had increased ROS levels (measured
with CM-H2DCFDA). Ebselen and mitoTEMPO were equally
efficient in reverting the migratory phenotype acquired upon
selection in vitro (SiHa-F3, Figure 3J, right panel) and in vivo
(B16-M4b, Figure 3K, right panel). Both drugs also totally sup-
pressed the enhanced migratory activity of SiHa-r0 that pro-
duced more ROS compared to WT cells (Figure 3L). These
data collectively demonstrate that the migratory phenotype
conferred by natural selection or by the experimental induction
of partial ETC inhibition can be totally blocked by specific
antioxidants.
Src Mediates Mitochondrial Superoxide-Dependent
Tumor Cell Migration by Activating Focal Adhesion
Kinase Pyk2
Several pathways could transduce promigratory mtROS sig-
nals. To identify a relevant effector, we performed a whole-
genome microarray comparing rotenone-treated B16F10,
B16-M2a, and B16-M4b to untreated B16F10 cells. A shared
gene signature was identified that comprised 27 upregulated
and 49 repressed genes (Table S1), among which focal adhe-
sion kinase (FAK) family member Ptk2b/Pyk2, known to pro-
mote metastasis downstream of Src (Wendt et al., 2013),
was induced. There was no shared signature of hypoxia-induc-
ible factor-1 (HIF-1). We therefore focused on Src and Pyk2,
previously reported to be ROS inducible (Cheng et al., 2002)
but for which information is still missing regarding responsive-
ness to mtROS in particular (Graham et al., 2012; Lluis et al.,
2007). We found that low-dose rotenone activates Src (Y416
phosphorylation) in the mitochondrial fraction of B16F10 cells,
which was blocked by mitoTEMPO (Figure 4A). MitoTEMPO
also decreased mitochondrial Src phosphorylation in B16-
M4b cells (Figure 4B). Downstream, Pyk2 transcription and
Pyk2 protein expression and activity (Y402 phosphorylation)
were increased in B16-M4b compared to B16F10 cells, and
all responses were repressed by mitoTEMPO (Figure 4C). Of
note, Pyk2 phosphorylation preceded its expressional induc-
tion, which was evidenced using low dose rotenone (Figure 4D),
and the effects of rotenone were also mitoTEMPO sensitive.
That Src lies upstream of Pyk2 in mtROS signaling was estab-
lished by showing that Src inhibitor PP1 repressed Pyk2 pro-
tein expression in B16-M4b and in rotenone-treated B16F10
cells (Figure 4E). Based on a previous report linking Src toCell Reports 8, 754–766, August 7, 2014 ª2014 The Authors 757
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SMAD activation (Wendt et al., 2013), we further found that
Pyk2 protein induction by mtROS involves transcriptional fac-
tors SMADs as it was repressed by an endoribonuclease-pre-
pared small interfering RNA (esiRNA) against SMAD4 (Figures
4F and S3A).
Next, we phenotypically linked the mtROS-Src-Pyk2 pathway
to tumor migration. Indeed, Src inhibitor PP1 blocked the migra-
tory phenotype of B16-M4b and of rotenone-treated B16F10
cells (Figure 4G), and SMARTpool Pyk2-specific siRNAs had
the same effect (Figure 4H; see Figure S3A for target extinction).
Coherently, the migratory phenotype of SiHa-F3 cells was also
abolished by PP1 and Pyk2 siRNA (Figures 4I and S3A) and
with the dual Pyk2/FAK inhibitor PF431396 (Figure S3B). Similar
responses were documented for SiHa-r0 cells (Figures S3A–
S3C). In naturally highly metastatic MDA-MB-231 human breast
cancer cells, Pyk2 also highly significantly contributed to cell
migration, and its expression was repressed by mitoTEMPO
(Figures S3A, S3D, and S3E). Altogether, these data evidence
that activation of Src-Pyk2 signaling by mtROS promotes tumor
cell migration, which can be targeted with the specific mitochon-
drial superoxide scavenger mitoTEMPO.
Mitochondrial ROS Scavenging Prevents Metastatic
Take in Mice
In the ETC, complexes I and III are the main sources of electron
leakage, hence of superoxide (Muller et al., 2004). To extend the
scope of our findings to metastatic hallmarks other than migra-
tion, we first focused on complex I. Compared with untreated
cells, B16F10 cells treated with low-dose rotenone showed
increased in vitro invasion (Figure 5A) and clonogenicity (Fig-
ure 5B) within the concentration range previously found to stim-
ulate migration without blocking respiration (see Figures 4B and
S4A). These responses closely reproduced the metastatic fea-
tures gained upon in vivo selection (Ishikawa et al., 2008a; see
also Figures 2C and 2D). We therefore tested in vivo the conse-
quences of tumor cell pretreatment with rotenone, and focused
on upstream mtROS. Compared to control, a 6 hr pretreatment
of B16F10 cells with 20 nM of rotenone (twice the optimal
in vitro dose to take into account possible in vivo washout) signif-
icantly promoted metastatic take in lungs after tail vein injection
in syngeneic mice (Figure 5C). An independent series of experi-
ments using the samemodel not only confirmed this observation
but further revealed that mitoTEMPO successfully prevented
the prometastatic effect of rotenone (Figure 5D), a property
that was not shared by mTTP (Figure S4B). The antimetastatic
effects of mitoTEMPO were similar to those observed with SrcFigure 3. Moderate OXPHOS Inhibition Promotes Tumor Cell Migratio
(A–D) SiHa-r0-D2 is a subclone of mitochondria-deficient SiHa-r0 cells. (A) Ro
lactate production over 24 hr (n = 3). Overnight (C) migration and (D) invasion (n
(E–I) SiHa-WT cells. (E) Overnight migration ± partial OXPHOS inhibition with low
10 mM, complex II inhibitor, n = 6), or a specific esiRNA against complex IV subu
cysteine (NAC, 5mM). (F) As in (E) but with increasing doses of rotenone (n = 6). (G)
6 hr treatment ± 10 nM of rotenone (n = 4). (H) Overnight migration ± rotenone (10 n
using the mitochondria-targeted superoxide-specific scavenger mitoTEMPO (50
(J–L) ROS production determined with CM-H2DCFDA (left, nR 8) and overnight
using SiHa-F3 (J), B16-M4b (K), and SiHa-r0 (L) cells and WT counterparts.
All data represent means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005, ns, not signifi
same treatment/cell type but without antioxidant, by Student’s t test (G; J–L, leftinhibitor saracatinib (suitable for in vivo use according to Dong
et al. [2010]; Figure S4C) and Pyk2 small hairpin RNA (shRNA)
(Figures S4D and S4E) in the same model, further illustrating
the involvement of mtROS-Src-Pyk2 signaling in metastasis. It
was confirmed with B16-M4b cells, because two different Pyk2
shRNAs blocked metastatic take (Figures S4F and S4E).
To broaden the scope of our findings beyond specific effects
of mitoTEMPO, we used mitoQ, a mitochondria-targeted form
of coenzyme Q10 (Kelso et al., 2001). MitoQ inhibited the meta-
static take of rotenone-pretreated B16F10 cells (Figure 5E),
whereas negative control decyl-TPP (dTPP) did not. These
data collectively demonstrate that mtROS promote metastatic
take, which can be blocked pharmacologically.
Mitochondrial ROS Scavenging Prevents Spontaneous
Tumor Metastasis in Mice
To test whether partial ETC inhibition also promotes sponta-
neous metastasis, we next focused on complex III. To this aim,
we used two different shRNAs (shUQCRB-1 and shUQCRB-2)
targeting ubiquinol-cytochrome c reductase binding protein
(UQCRB; Haut et al., 2003). Compared to cells expressing a con-
trol shRNA (shCTR), those with partial target extinction
(Figure S5A) showed a partial inhibition of mitochondrial O2
consumption (Figure 6A) and increased Pyk2 mRNA and protein
expression (Figure S5B), associated with increased in vitro
migration (Figure 6B), invasion (Figure 6C), and clonogenicity
(Figures 6D and S5C). These data validated the model to faith-
fully reproduce the phenotype of the B16-M variants selected
in vivo (Figures 2 and 4). In addition, shUQCRB promoted
both experimental (Figure S5D) and spontaneous (Figure 6E)
B16F10 metastasis compared to shCTR.
Finally, we tested whether mitochondrial superoxide scav-
enging with mitoTEMPO could be used to prevent spontaneous
tumor metastasis in vivo. We detected significantly less sponta-
neous lung metastases in the animals treated chronically with
mitoTEMPO (0.7 mg/kg, daily i.p.) compared to vehicle (Fig-
ure 6F). The therapeutic relevance of our observations was
further addressed in the orthotopic model of MDA-MB-231 hu-
man breast cancer cells in SCID mice. Ex vivo bioluminescence
of lungs 60 days after mammary fat-pad tumor cell implantation
revealed that mitoTEMPO totally prevented metastasis to the
lungs (only background luminescence was detected) by other-
wise spontaneously metastatic human tumors (Figure 6G). Of
note, mitoTEMPO did not modify primary tumor growth (Fig-
ure S5E) and did not induce overt toxicity when delivered chron-
ically to mice.n via Mitochondrial Superoxide
tenone-sensitive oxygen consumption (n = 3). (B) Glucose consumption and
R 6).
-dose rotenone (10 nM, targeting complex I, n = 6), 3-nitropropionate (3-NP,
nit mt-CO1 (n = 6, partial target extinction shown in Figure S2C) ± N-acetyl-L-
Mitochondrial superoxide productionmeasured usingmitoSOX in FACS after a
M, 6 hr) ormt-CO1 esiRNA ± antioxidant Ebselen (20 mM, n = 6). (I) As in (H) but
mM) instead of Ebselen (n = 6).
migration (right, n = 6 all) of cells ± Ebselen (20 mM) or ± mitoTEMPO (50 mM),
cant versus untreated WT cells; #p < 0.05, ##p < 0.01, ###p < 0.005 versus the
graphs) or one-way ANOVA (A–F, H, I; J–L, right graphs). See also Figure S2.
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DISCUSSION
This study aimed to determine whether tumor cells performing
aerobic glycolysis, the Warburg phenotype, are metastatic pro-
genitors. The selection of superinvasive and supermetastatic tu-
mor cells revealed a different phenotype that corresponds to a
dysfunction of the TCA cycle associated with increased succi-
nate and mitochondrial superoxide production. Mitochondrial
ATP production was preserved. Metastasis was also enhanced
upon partial ETC inhibition, another mitochondrial phenotype
that shares with natural selection the capacity to induce mito-
chondrial superoxide production. Based on these findings, we
document that spontaneous metastasis can be prevented with
the mitochondria-targeted superoxide scavenger mitoTEMPO,
with no overt toxicity.
Ishikawa et al. (2008a) previously showed that mtDNA muta-
tions can trigger tumor metastasis. The prometastatic mitochon-
drial phenotype that we identified is different. Selection followed
by biochemical characterization indeed revealed that super-
invasive (Figure 1) and supermetastatic (Figure 2) tumor cells
have undergone a common mitochondrial switch characterized
by increased succinate production with or without increased
glucose uptake and oxygen consumption, respectively. Super-
metastatic cells displayed unaltered mitochondrial ATP produc-
tion and no glycolytic compensation, thus ruling out the selection
of OXPHOS-inactivating mutations. Therefore, increased succi-
nate levels can be explained either by an overload of the TCA
cycle (which is supported by the acquisition of large mitochon-
dria with numerous cristae; Figure 2H), or by a dysfunction of
the TCA cycle downstream of succinate dehydrogenase. When
TCA cycle activity cannot be matched by ETC activity, mtROS
production increases (Wellen and Thompson, 2010). Accord-
ingly, we evidenced an increased mitochondrial superoxide pro-
duction that can be linked in our models to increased production
of electron donors, among which succinate can transfer elec-
trons to succinate dehydrogenase at ETC complex II (Dro¨se
and Brandt, 2012). Together, these observations indicate that
the mitochondrial switch that we identified depends on ETC
loading with excess electrons from the TCA cycle, without un-
coupling the ETC from ATP synthase. Contrary to aerobic glycol-
ysis, it did not provide a proliferative advantage (Figure S1B).
Conversely, moderate ETC inhibition can also promote tumor
metastasis. Ishikawa et al. (2008b) indeed showed that the trans-
fer of mitochondria with mtDNAmutations causing ETC complex
I dysfunction increased themetastatic activity ofweaklymetasta-Figure 4. A Src-SMAD-Pyk2 Pathway Accounts for mtROS-Induced Tu
Where indicated, cells were treated with 10 nM rotenone, 50 mM mitoTEMPO or
(A) Phospho-Y416-Src in the mitochondrial fraction of B16F10 cells (6 hr, nR 3)
(B) As in (A) but using supermetastatic B16-M4b cells (nR 3).
(C) Pyk2mRNA (left, 24 hr, nR 5) and Pyk2 (middle, 24 hr, nR 5) and phospho-Y
(D) Pyk2 (left, nR 5) and phospho-Y402-Pyk2 (right, nR 3) protein expression i
(E) Pyk2 protein expression in B16F10 and B16-M4b (left) and in B16F10 cells (r
(F) Pyk2 protein expression in B16F10 and B16-M4b 48 hr after transfection with
(G–I) Overnight migration. (G) Same cells and treatments as in (E) (n R 3). (H) W
Cells expressed control SMARTpool siRNAs (siCTR) or SMARTpool siRNAs aga
treated ± PP1 (left) or with control siRNA (siCTR) or a siRNA against Pyk2 (right,
All data represent means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005, ns, not signifi
same treatment/cell type but without antioxidant or PP1, by one-way ANOVA (Atic Lewis lung carcinoma cells (but it did not elicit de novometas-
tasis with nontransformed NIH 3T3 cells). Similar to ETC over-
loading, the prometastatic mitochondrial phenotype identified
by these authors depends on increased mtROS production.
Here, wewentmarkedly beyond this previous finding by showing
that partial inhibition (i.e., bottlenecking) of ETC complexes I to IV
conferred a ROS-mediated prometastatic phenotype: whereas
partial ETC inhibition improved tumor cell migration with all the
strategies that we tested, the use of specific antioxidants and
full ETC inhibition decreased migration (Figures 3A–3F). These
data support the tenets of a hormetic window for mitochondrial
ROS where moderate increase promotes tumorigenesis,
whereas mtROS production above prometastatic levels would
causecell death (SenaandChandel, 2012;Weinberg et al., 2010).
Excessive and deficient ETC activities generated the same su-
peroxide-dependent prometastatic phenotype,which suggested
the possibility of a common downstream mechanism. ROS in
general and mtROS in particular are well known to contribute to
tumor growth (Cannito et al., 2010; Dewhirst, 2009; Ferraro
et al., 2006; Finley et al., 2011; Gao et al., 2007; Ishikawa et al.,
2008a, 2008b;Miura et al., 2004; Nazarewicz et al., 2013a;Wein-
berg et al., 2010). Mitochondrial superoxide originates from elec-
tron leak at ETC complexes I and III (Muller et al., 2004). There,
excess electrons are transferred to O2 to form superoxide and,
downstream, H2O2 (Wellen and Thompson, 2010). Using the
antioxidants NAC and Ebselen, we showed H2O2 to be a pivotal
promigratory effector of both metabotypes (Figure 3). Down-
stream of mtROS, both ETC dysfunctions further shared the abil-
ity to stimulate Src-Pyk2 signaling (Figures 4, S3, S4C, S4D, S5A,
and S5B). Interestingly, Src activation occurred in the mitochon-
drial fraction of the cells (Figures 4A and 4B) and was unchanged
in whole-cell lysates (not shown), highlighting it as a most up-
stream signaling event. Further downstream, Src induced the
expression of Pyk2, a FAK familymember protein tyrosine kinase
that was previously reported to promote cytoskeletal remodeling
and themigration, survival and epithelial-to-mesenchymal transi-
tion (EMT) of adherent cells (Gelman, 2003; Wendt et al., 2013).
Unlike FAK, which is ubiquitously expressed, Pyk2 expression
is inducedby chemokines, TGF-b signaling, and following activa-
tion of G-protein-coupled receptors (Wendt et al., 2013). Our
work indicates that mtROS can be included among pathophysio-
logical inducers, with mitochondrial superoxide increasing Src-
dependent, SMAD-induced Pyk2 transcription (Figure 4F), and
activation (Figure 4), in agreement with previous reports indi-
cating that ROS can activate Src, and showing that Pyk2 actsmor Cell Migration
10 mM of Src inhibitor PP1.
.
402-Pyk2 (right, 6 hr, nR 3) protein expression in B16F10 and B16-M4b cells.
n B16F10 cells (24 hr, nR 3).
ight, 24 hr, nR 3).
a control esiRNA (control) or a SMAD4-specific esiRNA (n = 3).
T B16F10 versus supermetastatic B16-M4b cells (left); B16F10 cells (right).
inst Pyk2 (siPYK2, nR 5 all). (I) SiHa-WT versus superinvasive SiHa-F3. Cells
nR 4 all).
cant versus untreated/WT cells; #p < 0.05, ##p < 0.01, ###p < 0.005 versus the
, C–I) or by Student’s t test (B). See also Table S1 and Figure S3.
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Figure 5. Mitochondrial ROS Scavenging
Prevents Metastatic Take
(A–E) B16F10 tumor cells were treated with rote-
none where indicated.
(A) Invasion assay (rotenone 10 nM, n = 3).
(B) Clonogenic assays (nR 3) with cells pretreated
for 6 hr with the indicated doses of rotenone.
(C) Experimental metastasis assay with B16F10
tumor cells constitutively expressing luciferase
(B16F10-LUC) treated for 6 hr with 20 nM of
rotenone or vehicle before tail vein injection. Mice
were sacrificed 15 days later. Representative
pictures of the lungs are shown and the number of
lung metastases is quantified in the graph (n = 6).
(D) Determination of the number of lung metasta-
ses in syngeneic mice 15 days after the tail vein
injection of B16F10 tumor cells treated with 20 nM
rotenone and/or 50 mM of the mitochondria-se-
lective superoxide-specific scavenger mito-
TEMPO. Representative pictures of the lungs are
shown and the number of lung metastases is
quantified in the graph (nR 5).
(E) As in (D) but using 1 mM of the mitochondria-
targeted antioxidant mitoQ or dTPP (n = 4–5).
All data represent means ± SEM. *p < 0.05, **p <
0.01, ***p < 0.005, by Student’s t test (A), one-way
ANOVA (B, D, and E), or Mann-Whitney (C). See
also Figure S4.downstream of both ROS and Src (Andreev et al., 2001; Chiarugi
et al., 2003; Gelman, 2003; Graham et al., 2012; Lluis et al., 2007;
Wendt et al., 2013). Overall, Pyk2 is evidenced to be amainmedi-
ator of mitochondrial superoxide signaling, because its specific
inhibition with si/shRNAs recapitulated the antimigratory and
antimetastatic effects of mitoTEMPO (Figures 4G–4I and S4D–
S4F). Our microarray data nevertheless suggest that additional
effectors are likely to be involved.
We exploited the rationale provided by our in vitro findings
to evaluate mtROS scavengers, targeting the most upstream
mitochondrial event that was identified, in metastasis preven-
tion. In different human and mouse models, the metastatic762 Cell Reports 8, 754–766, August 7, 2014 ª2014 The Authorsphenotype as a whole was lost when tu-
mor-bearing mice were treated with the
superoxide scavenger mitoTEMPO that
we preferred to other common antioxi-
dants for its high tropism formitochondria
(TPP group) and for its demonstrated
specificity for superoxide (Dikalova
et al., 2010; Nazarewicz et al., 2013a;
Zhou et al., 2011). In particular, we report
that mitoTEMPO prevents spontaneous
metastasis of naturally metastatic MDA-
MB-231 human breast cancer cells im-
planted orthotopically in themousemam-
mary fat pad (Figure 6G). Many anti-
cancer therapies rely on ROS-induced
apoptosis. Although generic antioxidant
effects on tumor growth are still debated
(Gao et al., 2007; Sayin et al., 2014), mito-
TEMPOcompared to less selective antioxidants preserves phys-
iological ROS signaling (as shown in nonmalignant fibroblasts;
Nazarewicz et al., 2013a) and could therefore selectively target
tumor cells with abnormal mitochondrial activities. Although we
did not find significant primary tumor growth inhibition using mi-
toTEMPO at 0.7 mg/kg/day (Figure S5E), others (Nazarewicz
et al., 2013a) have shown that the therapeutic effects of this
drug at higher dose may retard primary tumor growth. Mito-
TEMPO acts as a SOD2 mimetic (Dikalova et al., 2010), raising
the question of its impact on mitochondrial ROS detoxification,
because it would promote H2O2 formation. In fact, by decreasing
mitochondrial superoxide levels, mitoTEMPO impairs the
Figure 6. Mitochondrial ROS Scavenging Prevents Metastatic Tumor Dissemination
(A–E) B16F10 tumor cells were expressing specific shRNAs against complex III subunit ubiquinol-cytochrome c reductase binding protein (shUqcrb-1 or
shUqcrb-2) or a control shRNA.
(A) Rotenone-sensitive oxygen consumption (nR 3).
(B) Overnight migration (nR 11).
(C) Overnight invasion (nR 3).
(D) Clonogenicity (n = 6).
(legend continued on next page)
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formation of many different ROS derived fromO2, including cyto-
solic H2O2 (Nazarewicz et al., 2013b; Rogers et al., 2014) and
self-propagating lipid peroxides (Mylonas and Kouretas, 1999),
supporting efficient ROS detoxification. Similar to mitoTEMPO,
mitoQ, a mitochondria-targeted form of coenzyme Q10 currently
tested in clinical trials for applications other than cancer (Jin
et al., 2013), blocked metastatic take (Figure 5). Collectively,
these findings offer a rationale to test mitochondria-targeted su-
peroxide scavengers, including mitoQ, in metastasis prevention
trials.
In conclusion, we identified that aberrant TCA cycling coupled
to mitochondrial superoxide production promotes tumor cell
migration and metastasis. It represents a naturally selected,
evolutionary alternative to ETC defects that also promote super-
oxide-dependent metastasis. Thus, tumor cells with increased
mitochondrial superoxide production constitute a population of
metastatic progenitors, and mitochondrial superoxide scav-
enging can be proposed as a therapeutic option to prevent spon-
taneous human tumor metastasis.
EXPERIMENTAL PROCEDURES
Animal Ethics Statement
All in vivo experiments were conducted under approval of the Universite´ cath-
olique de Louvain (UCL) authorities (Comite´ d’Ethique Facultaire pour l’Expe´r-
imentation Animale) according to national animal care regulations. Specific
approval ID for this study was TUMETABO.
Cell Lines and Reagents
All assayswere performed in DMEMwith 4.5 g/l glucosewithout glutamine, py-
ruvate, and serum unless stated otherwise. SiHa human cervix squamous cell
carcinoma and B16F1 and B16F10 murine melanoma tumor cells were pur-
chased from ATCC, MDA-MB-231-LUC-D3H2LN human breast cancer cells
and B16F10-LUC cells expressing firefly luciferase were fromCaliper, andmu-
rine breast cancer cells 4T1were a kind gift fromProf. Fred R.Miller (Karmanos
Cancer Institute, Detroit, MI). These cells were routinely grown in DMEM con-
taining glutamax and 4.5 g/l glucose supplemented with 10% fetal bovine
serum (Gibco) and penicillin-streptomycin (Sigma-Aldrich) in a humidified at-
mosphere with 5% CO2 at 37
C. For the generation of mitochondria-defective
r0 cells, SiHa cells were treated with low-dose ethidium bromide (50 ng/ml) for
7 weeks and grown as previously described (Desjardins et al., 1986). SiHa-r0-
D2 is a clonal cell line obtained by the limiting dilution of SiHa-r0. MitoTEMPO
was from Santa-Cruz, PP1 and the Pyk2 inhibitor PF431396 from Abcam.
MitoQ, and decyl-TPP were kind gifts of Prof. Michael P. Murphy. All other
reagents were from Sigma-Aldrich and were dissolved in a DMSO vehicle.
Selection of Superinvasive and Supermetastatic Tumor Cells
Superinvasive SiHa-F3 cells were selected following three rounds of in vitro
selection in BD BioCoat transwells (see Figure 1A). Supermetastatic B16-
Mxy (where x represents the selection round and y independent selection iden-
tification) tumor cells were obtained by rounds of in vivo selection starting from
WT B16F10 (see Figure 2A).
Functional Assays In Vitro
Cell migration and invasion were assayed in transwells, clonogenicity on soft
agar, and proliferation with bromodeoxyuridine.(E) Spontaneous metastasis assay: lung metastases were counted under a stere
pictures of the lungs are shown (including at 53 magnification; scale bars, 200 m
(F and G) Daily i.p. injections of mitoTEMPO (0.7 mg/kg) prevented spontaneous
B16-M4b cells (metastases counted under a stereoscopic microscope, n R 9),
quantified using bioluminescence, nR 6).
All data represent means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005, by one-way A
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To avoid differences due to unequal growth rates, all measurements were
made starting with confluent cells. All data were normalized by cell numbers.
Oximetry was performed on a Seahorse XF96 bioenergetic analyzer and
with electron paramagnetic resonance (EPR, Figure 6A). All data show mito-
chondrial oxygen consumption. The dose-dependent effect of rotenone on ox-
ygen consumption was determined using MitoXpress (Luxcel Biosciences). All
metabolic assays used enzymatic reactions with cells incubated for 24 hr in
DMEM without glutamine, pyruvate, and serum.
Electron Microscopy
Transmission electron microscopy was performed using a previously
described protocol (Piret et al., 2012).
ROS Measurements
MitoSOX was used to measure superoxide levels but has limited sensitivity
and may not be fully selective for superoxide (Zielonka and Kalyanaraman,
2010). For this reason, ROS levels were measured with CM-H2DCFDA, and
the specific contribution of mtROS was verified in functional assays with spe-
cific inhibitors.
Cell Transfection, Quantitative RT-PCR, Immunoblotting, and
Microarrays
Cell transfection with RNAi/MAX (Invitrogen) and infection with a third-gener-
ation lentiviral system are detailed in Supplemental Experimental Procedures.
Quantitative RT-PCR and immunoblotting used previously disclosed protocols
(Bouzin et al., 2007; Chianale et al., 2010). Following RNA isolation, whole-
genome expression analysis was performed at Arraystar.
Metastatic Take and Spontaneous Metastasis Assays
For metastatic take assays, tumor cells were pretreated for 6 hr with the indi-
cated drugs, and 106 viable cells were injected into the tail vein of syngeneic
mice. For spontaneous metastasis assays, tumor cells were injected ortho-
topically to syngeneic or SCIDmice to form primary tumors that were surgically
removed when reaching a diameter of approximately 1 cm. Mice were treated
daily with mitoTEMPO (0.7 mg/kg) or vehicle.
Statistics
All data are presented as means ± SEM. Student’s t test, Mann-Whitney test
and one-way ANOVA (Bonferroni post hoc test) were used where appropriate.
p < 0.05 was considered statistically significant.
ACCESSION NUMBERS
Microarray data are available in the ArrayExpress database (http://www.ebi.
ac.uk/arrayexpress) under accession number E-MTAB-2656.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.06.043.
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